The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
Abstract
PURPOSE: This is the first published report on the validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer. The FACT-B consists of the FACT-General (FACT-G) plus the Breast Cancer Subscale (BCS), which complements the general scale with items specific to QL in breast cancer. The FACT-B was developed with an emphasis on patients' values and brevity and is available in nine languages. METHODS AND RESULTS: Two validation samples were used for this report. The first (n = 47) was tested twice over a 2-month period to assess sensitivity to change. Significant sensitivity to change in performance status rating (PSR) was demonstrated for the FACT-B total score, the Physical Well-Being (PWB) subscale, the Functional Well-Being (FWB) subscale, and the BCS. Sensitivity to change in QL as measured by the Functional Living Index-Cancer (FLIC) was documented in the FACT-B total score, PWB, FWB, and Emotional Well-Being (EWB). Additional validity and reliability data were obtained from a larger sample (n = 295). The alpha coefficient (internal consistency) for the FACT-B total score was high (alpha = .90), with subscale alpha coefficients ranging from .63 to .86. Evidence supported test-retest reliability, as well as convergent, divergent, and known groups validity. CONCLUSION: The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice. It demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observed mean improvements presented within this evaluation exceeded this for both groups.”
In the citing paper
“All measures were validated, brief, and non-redundant, supporting parsimony while enabling comprehensive evaluation of intervention impact.”
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Impact of Event Scale: A Measure of Subjective Stress
Horowitz, M., Wilner, N., & Alvarez, W. (1979) · Psychosomatic Medicine · doi:10.1097/00006842-197905000-00004 · Cited by 7,813
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citationShort, homogeneous versions of the Marlow-Crowne Social Desirability Scale
Strahan, R. F., & Gerbasi, K. C. (1972) · Journal of Clinical Psychology · doi:10.1002/1097-4679(197204)28:2 · Cited by 1,657
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220
Estimates of the worldwide frequency of sixteen major cancers in 1980
Parkin, D. M., Läärä, E., & Muir, C. S. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410205 · Cited by 1,057
Schipper, H., Clinch, J., McMurray, A., & Levitt, M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.472 · Cited by 1,052
Zubrod, C. G., Schneiderman, M. A., Frei, E., Brindley, C. O., Gold, G. L., Shnider, B. I., Oviedo, R., Gorman, J. G., Jones, R., Jonsson, U., et al. (1960) · Journal of Chronic Diseases · doi:10.1016/0021-9681(60)90137-5 · Cited by 1,034
Who should measure quality of life, the doctor or the patient?
Slevin, M., Plant, H., Lynch, D., Drinkwater, J., & Gregory, W. M. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.20 · Cited by 903
Cited by
Sorted by citations
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104
Self-citationAmerican College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., GALVÃO, D. A., Pinto, B. M., IRWIN, M. L., WOLIN, K. Y., SEGAL, R. J., LUCIA, A., et al. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e0c112 · Cited by 2,781
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citationMansel, R. E., Fallowfield, L. J., Kissin, M. W., Goyal, A., Newcombe, R. G., Dixon, J. M., Yiangou, C., Horgan, K. J., Bundred, N. J., Monypenny, I. J., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj158 · Cited by 1,679
Metadata
- Authors
- Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G.
- Affiliations
- Rush University Medical Center (US)
- Rush University (US)
- Venue
- Journal of Clinical Oncology
- Published
- 1997-03
- Volume
- 15
- Issue
- 3
- Pages
- 974-986
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1857624176
- Cited by
- 1,752
- References
- 39
- Citations by year
- 2026: 47 · 2025: 76 · 2024: 77 · 2023: 71 · 2022: 97 · 2021: 88 · 2020: 78 · 2019: 87 · 2018: 83 · 2017: 85 · 2016: 83 · 2015: 73 · 2014: 83 · 2013: 70 · 2012: 86
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r29ca051926-01a1)
- National Cancer Institute (R29CA51926)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Nursing › Research and Theory › Health Education and Validation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- FACT-B, breast cancer, quality of life, FACT-G, instrument validation, sensitivity to change, test-retest reliability, internal consistency, known-groups validity, convergent validity, discriminant validity, physical well-being, functional well-being, emotional well-being, Functional Living Index-Cancer, self-report questionnaire
- MeSH terms
- Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Quality of Life, Self Concept, Sensitivity and Specificity, Severity of Illness Index, Translations, Reproducibility of Results
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review